SEPTInvestingStart Free

EDSA 8-K: Contract win

Edesa Biotech

Filed with the SEC on · accession 0001171843-26-007242

EDSA filed a 8-K (current report) with the SEC on Nov 9, 2026. Edesa Biotech entered a Collaboration and License Agreement with Kyorin Pharmaceutical granting exclusive rights to develop and commercialize its anti-TLR4 antibody paridiprubart (EB05) for ARDS in Japan, receiving a $12 million upfront payment plus up to $55 million in development/regulatory…

Summary of the filing

Edesa Biotech entered a Collaboration and License Agreement with Kyorin Pharmaceutical granting exclusive rights to develop and commercialize its anti-TLR4 antibody paridiprubart (EB05) for ARDS in Japan, receiving a $12 million upfront payment plus up to $55 million in development/regulatory milestones and up to ¥12.0 billion in sales milestones. The company also terminated its at-the-market offering agreement with H.C. Wainwright effective November 16, 2026.

For details, click here →How to read a 8-K →

Key details

upfront payment$12.0M
aggregate development and regulatory milestone payments$55.0M
aggregate sales-based milestone paymentsJPY 12.0B
LicensorEdesa Biotech, Inc.
LicenseeKyorin Pharmaceutical Co., Ltd.
Terminated atm sales agentH.C. Wainwright & Co., LLC
Upstream licensor of paridiprubartNovImmune SA (Light Chain Bioscience)

✦ Ask GOAX AI about this filing — what it means for EDSA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for EDSA?

Click here

Frequently asked questions

What did EDSA file with the SEC on Nov 9, 2026?

EDSA filed a 8-K (Contract win). Edesa Biotech entered a Collaboration and License Agreement with Kyorin Pharmaceutical granting exclusive rights to develop and commercialize its anti-TLR4 antibody paridiprubart (EB05) for ARDS in Japan, receiving a $12 million upfront payment plus up to $55 million in development/regulatory milestones and up to ¥12.0 billion in sales milestones. The company also terminated its at-the-market offering agreement with H.C. Wainwright effective November 16, 2026.

What does a contract win mean for EDSA stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other EDSA SEC filings

Get alerts when EDSA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
EDSA overviewEDSA analysisEDSA newsLatest SEC filings